Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guangzhou Doublle Bioproduct
Guangzhou, Guangdong Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Adenolysin, a recombinant human endostatin adenovirus gene therapy, showed encouraging results in its China Phase 3 trial for head and neck cancer, with evidence of clinical benefit for patients in this indication.
- Therapeutic areas
- OncologyNephrologyGastroenterology
- Modalities
- Gene therapyCell therapyMonoclonal antibodyNatural killer cell therapy
- Industry
- Biotech
02
Partnerships
The Sage Group Inc. (for global partnering of Adenolysin)
Beyond the preview
Go deeper on Guangzhou Doublle Bioproduct.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Doublle Bioproduct.